<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04711070</url>
  </required_header>
  <id_info>
    <org_study_id>MCIM</org_study_id>
    <nct_id>NCT04711070</nct_id>
  </id_info>
  <brief_title>Understanding the Mechanisms of Critical Illness Myopathy by Use of a Novel Electrophysiological Method - MVRCs</brief_title>
  <official_title>Understanding the Mechanisms of Critical Illness Myopathy by Use of a Novel Electrophysiological Method - Muscle Velocity Recovery Cycles (MVRCs)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Sándor Beniczky</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Danish Council for Independent Research</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>University of Aarhus</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Søster og Verner Lipperts Fond</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Aarhus University Hospital</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Critical illness myopathy (CIM) is a disabling condition that develops in critically ill&#xD;
      patients. The syndrome is not only a cause of prolonged intensive care hospitalisation but&#xD;
      also a main reason for delayed recovery. Critical illness myopathy presents as diffuse muscle&#xD;
      weakness and failure to wean from mechanical ventilation.&#xD;
&#xD;
      The pathogenesis of CIM is unclear. The proposed mechanisms for critical illness myopathy&#xD;
      include muscle membrane depolarization, circulating depolarizing factor, and an endotoxin&#xD;
      that reduces muscle sodium channel availability at depolarized membrane potentials.&#xD;
&#xD;
      The electrophysiological diagnosis of CIM diagnosis is done by electromyography (EMG). In&#xD;
      order to be able to detect changes in EMG, more than 2-3 weeks' time is required. Moreover&#xD;
      the findings resemble other myopathies and are unspecific. EMG studies in paralysed muscles&#xD;
      and sometimes unconscious patients is difficult or even impossible&#xD;
&#xD;
      Since the 1950s, it has been attempted to investigate the muscle cell membrane properties,&#xD;
      but it has not been possible to develop a clinically applicable diagnostic method. The novel&#xD;
      electrophysiological method MVRCs is a possible future diagnostic method. It's more sensitive&#xD;
      to muscle cell membrane changes than existing methods and it is simple enough to use in&#xD;
      multiple clinical settings.&#xD;
&#xD;
      The objective of this study is to investigate the utility of MVRCs in the early diagnosis of&#xD;
      critical illness myopathy by investigating the muscle membrane properties in sepsis patients,&#xD;
      who are in risk of developing CIM. In addition, this will contribute to a better&#xD;
      understanding of the pathophysiology of critical illness myopathy.&#xD;
&#xD;
      The study will enrol 70 participants in total, divided in to 2 groups of 20 patients aged ≥18&#xD;
      years; 1) patients with sepsis at intensive care units and 2) patients with chronic renal&#xD;
      failure and uremia, and 30 sex- and aged-matched healthy participants. All subjects are to&#xD;
      undergo neurological examinations, electromyography, nerve conduction studies, direct muscle&#xD;
      stimulation and MVRCs. Blood tests will be taken in all patients. Patients with sepsis will&#xD;
      be examined every week in 3 weeks. The presence of probable CIM will be determined on the 4th&#xD;
      examination. Healthy participants and patients with chronic renal failure will only be&#xD;
      examined in 1 occasion.&#xD;
&#xD;
      The primary outcomes will be MVRCs parameters which will be compared between patients and&#xD;
      healthy participants. Furthermore, MVRCs parameters will be correlated to blood sample&#xD;
      results.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">January 4, 2021</start_date>
  <completion_date type="Anticipated">March 31, 2023</completion_date>
  <primary_completion_date type="Anticipated">December 31, 2022</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Muscle relative refractory period (MRRP)</measure>
    <time_frame>12 weeks</time_frame>
    <description>Measurement of changes in muscle membrane properties by MVRCs.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Early supernormality (ESN)</measure>
    <time_frame>12 weeks</time_frame>
    <description>Measurement of changes in muscle membrane properties by MVRCs.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Late supernormality (LSN)</measure>
    <time_frame>12 weeks</time_frame>
    <description>Measurement of changes in muscle membrane properties by MVRCs.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Extra late supernormality (XLSN)</measure>
    <time_frame>12 weeks</time_frame>
    <description>Measurement of changes in muscle membrane properties by MVRCs.</description>
  </secondary_outcome>
  <number_of_groups>3</number_of_groups>
  <enrollment type="Anticipated">70</enrollment>
  <condition>Critical Illness Myopathy</condition>
  <condition>Myopathy Critical Illness</condition>
  <arm_group>
    <arm_group_label>Patients with sepsis</arm_group_label>
    <description>Muscle velocity recovery cycles, electromyography, nerve conduction studies, direct musclestimulation, blood test</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Patients with chronic renal failure</arm_group_label>
  </arm_group>
  <arm_group>
    <arm_group_label>Healthy control</arm_group_label>
  </arm_group>
  <eligibility>
    <study_pop>
      <textblock>
        Patients: Recruited from patients hospitalized in Intensive Care Units at the Department of&#xD;
        Anaesthesiology and Intensive Care, Aarhus University Hospital.&#xD;
&#xD;
        Healthy participants: Recruitment posters at Aarhus University, Aarhus University Hospital&#xD;
        and at http://www.forsoegsperson.dk/.&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
        Patients: Fulfilled sepsis criteria of an increase in the Sequential (Sepsisrelated) Organ&#xD;
        Failure Assessment (SOFA) score of 2 points or more.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
        Patients and controls:&#xD;
&#xD;
          -  Earlier peripheral nervous system disease&#xD;
&#xD;
          -  History of malignancy, diabetes mellitus, alcoholism, medicine or other causes of&#xD;
             polyneuropathy or myopathy&#xD;
&#xD;
          -  Bleeding tendency or anticoagulation therapy&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Hatice H Tankisi, MD, PhD</last_name>
    <role>Study Chair</role>
    <affiliation>Aarhus Universitetshospital</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Lotte H Larsen, Stud.med.</last_name>
    <phone>004523366988</phone>
    <email>lottlr@rm.dk</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Hatice Tankisi, MD, PhD</last_name>
    <phone>004578462431</phone>
    <email>hatitank@rm.dk</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Department of Anaesthesiology and Intensive Care, Aarhus University Hospital</name>
      <address>
        <city>Aarhus C</city>
        <zip>8000</zip>
        <country>Denmark</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Alp Tankisi, MD, PhD</last_name>
    </contact>
    <contact_backup>
      <last_name>Stig E Dyrskog, MD, PhD</last_name>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>Department of Clinical Neurophysiology, Aarhus University Hospital</name>
      <address>
        <city>Aarhus C</city>
        <zip>8000</zip>
        <country>Denmark</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location_countries>
    <country>Denmark</country>
  </location_countries>
  <verification_date>January 2021</verification_date>
  <study_first_submitted>January 13, 2021</study_first_submitted>
  <study_first_submitted_qc>January 13, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">January 15, 2021</study_first_posted>
  <last_update_submitted>January 13, 2021</last_update_submitted>
  <last_update_submitted_qc>January 13, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">January 15, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>Aarhus University Hospital</investigator_affiliation>
    <investigator_full_name>Sándor Beniczky</investigator_full_name>
    <investigator_title>Professor</investigator_title>
  </responsible_party>
  <keyword>Critical Illness Myopathy</keyword>
  <keyword>Muscle Velocity Recovery Cycles</keyword>
  <keyword>Intensive Care Unit</keyword>
  <keyword>Sepsis</keyword>
  <keyword>Diagnosis</keyword>
  <keyword>Pathophysiology</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Muscular Diseases</mesh_term>
    <mesh_term>Critical Illness</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

